Comparative Outcomes of GH Treatment in Pediatric Idiopathic Short Stature and GH Deficiency
GH treatment over 5 to 10 years effectively increased height in children with ISS and children with GHD, including those who reached NAH, with a favorable benefit-risk profile.
Authors
- M. Jennifer Abuzzahab
- Moshe Phillip (ORCID: https://orcid.org/0000-0002-6616-5612)
- Lars Sävendahl (ORCID: https://orcid.org/0000-0003-1067-4976)
- Primož Kotnik (ORCID: https://orcid.org/0000-0001-9570-1130)
- Alberto Pietropoli (ORCID: https://orcid.org/0000-0003-0353-4334)
- Jean-Marc Ferran
- Nicky Kelepouris (ORCID: https://orcid.org/0000-0003-2445-2338)
- Michel Polak
- Michael Højby
Institutions
- Hôpital Necker-Enfants Malades (FR)
- Statistics Denmark (DK)
- Children’s Minnesota - St. Paul Hospital (US)
- Karolinska University Hospital (SE)
- Inserm (FR)
- Tel Aviv University (IL)
- Novo Nordisk (Denmark) (DK)
- Université Paris Cité (FR)
- Al-Quds University (PS)
- Ljubljana University Medical Centre (SI)
- Karolinska Institutet (SE)
- Novo Nordisk (United States) (US)
- Novo Nordisk (Switzerland) (CH)
- Schneider Children's Medical Center (IL)
Publication Details
- Journal
- Journal of the Endocrine Society
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1210/jendso/bvaf133
- Citations
- 2
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Pfizer
- Sanofi
- Agence Nationale de la Recherche
- Novo Nordisk
- Ipsen